Edition:
United States

Zogenix Inc (ZGNX.OQ)

ZGNX.OQ on NASDAQ Stock Exchange Global Market

47.86USD
3:59pm EST
Change (% chg)

$0.29 (+0.61%)
Prev Close
$47.57
Open
$47.56
Day's High
$48.45
Day's Low
$47.00
Volume
86,452
Avg. Vol
167,650
52-wk High
$62.75
52-wk Low
$33.56

Latest Key Developments (Source: Significant Developments)

Zogenix announces positive phase 3 trial results on the efficacy and safety of Fintepla (Zx008) in dravet syndrome
Monday, 3 Dec 2018 09:00am EST 

Dec 3 (Reuters) - Zogenix Inc ::ZOGENIX ANNOUNCES POSITIVE PHASE 3 TRIAL RESULTS ON THE EFFICACY AND SAFETY OF FINTEPLA® (ZX008) IN DRAVET SYNDROME.ZOGENIX INC - CLINICALLY MEANINGFUL REDUCTION IN CONVULSIVE SEIZURE FREQUENCY FOR FINTEPLA MAINTAINED OVER PHASE 3 OPEN-LABEL EXTENSION TRIAL.ZOGENIX INC - STUDY 1504 MET PRIMARY ENDPOINT AND ALL KEY SECONDARY ENDPOINTS.ZOGENIX INC - RESULTS DEMONSTRATED STATISTICALLY SIGNIFICANT EFFICACY OF FINTEPLA.ZOGENIX INC - STUDY ALSO DEMONSTRATED STATISTICALLY SIGNIFICANT DIFFERENCES IN SEIZURE-FREE INTERVALS.ZOGENIX INC - INCIDENCE OF SERIOUS ADVERSE EVENTS WAS SIMILAR IN BOTH TREATMENT AND PLACEBO GROUPS.ZOGENIX - MOST COMMON ADVERSE EVENTS IN FINTEPLA GROUP WERE DECREASED APPETITE (44%), PYREXIA (26%), FATIGUE (26%), DIARRHEA (23%), NASOPHARYNGITIS (16%).ZOGENIX INC - ACROSS ALL TRIALS, NO SAFETY SIGNAL OF ANY VALVULAR HEART DISEASE HAS BEEN IDENTIFIED TO DATE.  Full Article

Zogenix Q3 Loss Per Share $1.08
Thursday, 8 Nov 2018 04:01pm EST 

Zogenix Inc ::ZOGENIX PROVIDES CORPORATE UPDATE AND REPORTS THIRD QUARTER FINANCIAL RESULTS.Q3 LOSS PER SHARE $1.08.Q3 EARNINGS PER SHARE VIEW $-0.88 -- THOMSON REUTERS I/B/E/S.  Full Article

Zogenix Announces Positive Top-Line Results From Second Pivotal Phase 3 Clinical Trial Of Zx008 In Dravet Syndrome
Thursday, 12 Jul 2018 07:00am EDT 

July 12 (Reuters) - Zogenix Inc ::ZOGENIX ANNOUNCES POSITIVE TOP-LINE RESULTS FROM SECOND PIVOTAL PHASE 3 CLINICAL TRIAL OF ZX008 IN DRAVET SYNDROME.ZOGENIX INC - ZX008 ALSO DEMONSTRATED STATISTICAL SIGNIFICANCE IN ALL KEY SECONDARY ENDPOINTS.ZOGENIX INC - U.S. AND EU REGULATORY SUBMISSIONS ON TRACK FOR Q4 OF 2018.ZOGENIX - PRIMARY ENDPOINT ACHIEVED - STATISTICALLY SIGNIFICANT CONVULSIVE SEIZURE REDUCTION FOR ZX008 VERSUS PLACEBO FOR ADJUNCTIVE TREATMENT OF SEIZURES.ZOGENIX INC - ZX008 ALSO DEMONSTRATED STATISTICALLY SIGNIFICANT IMPROVEMENT VERSUS PLACEBO IN BOTH KEY SECONDARY MEASURES.ZOGENIX - ZX008 GENERALLY WELL-TOLERATED IN STUDY WITH ADVERSE EVENTS CONSISTENT WITH THOSE OBSERVED IN STUDY 1 & KNOWN SAFETY PROFILE OF FENFLURAMINE.  Full Article

Zogenix Says Repaid Entire $20.1 Mln Of Outstanding Principal & Interest Under Its Loan And Security Agreement
Friday, 29 Dec 2017 04:11pm EST 

Dec 29 (Reuters) - Zogenix Inc ::ZOGENIX SAYS REPAID IN FULL ENTIRE $20.1 MILLION OF OUTSTANDING PRINCIPAL & INTEREST UNDER ITS LOAN AND SECURITY AGREEMENT DATED AS OF DEC 30, 2014.ZOGENIX SAYS IN CONNECTION WITH REPAYMENT, CO WAS ALSO REQUIRED TO MAKE FINAL PAYMENT OF ABOUT $1.4 MILLION, OTHER PAYMENTS - SEC FILING.  Full Article

Zogenix Announces New Data From Pivotal Phase 3 Clinical Trial Of ZX008
Monday, 4 Dec 2017 08:00am EST 

Dec 4 (Reuters) - Zogenix Inc ::ZOGENIX ANNOUNCES NEW POSITIVE EFFICACY AND SAFETY DATA FROM PIVOTAL PHASE 3 CLINICAL TRIAL OF ZX008 IN DRAVET SYNDROME.ZOGENIX INC - DATA SHOWS ZX008 PATIENTS MORE LIKELY TO ACHIEVE CLINICALLY MEANINGFUL REDUCTION IN SEIZURE FREQUENCY COMPARED TO THOSE ON PLACEBO.ZOGENIX INC - LOOK FORWARD TO SHARING TOP-LINE RESULTS FROM SECOND PIVOTAL PHASE 3 TRIAL OF ZX008, STUDY 1504, IN Q2 OF 2018.  Full Article

Zogenix Announces Initiation Of Phase 3 Trial For ZX008 In Lennox-Gastaut Syndrome
Wednesday, 29 Nov 2017 08:05am EST 

Nov 29 (Reuters) - Zogenix Inc ::ZOGENIX ANNOUNCES INITIATION OF PHASE 3 TRIAL FOR ZX008 IN LENNOX-GASTAUT SYNDROME.  Full Article

Zogenix posts Q3 loss of $1.68 per share
Tuesday, 7 Nov 2017 04:01pm EST 

Nov 7 (Reuters) - Zogenix Inc :Zogenix provides corporate update and reports third quarter 2017 financial results.Q3 earnings per share view $-0.93 -- Thomson Reuters I/B/E/S.Q3 loss per share $1.68.At September 30, 2017, company had cash and cash equivalents of $64.7 million, compared to $91.6 million at December 31, 2016​.  Full Article